&w=3840&q=100)
₹6,500 cr realty shake-up: Commercial deals soar 2X, residential slumps
Supporting this trend, Grant Thornton Bharat's Real Estate Q2 2025 Dealtracker revealed that the sector recorded transactions worth $2.5 billion (approx. ₹20,875 crore) in the first half of the year. Although that marks an 8% decline from $2.7 billion in H1 2024, the volume of deals actually rose—from 40 last year to 45 this year—highlighting deeper market participation.
Total Deal Value: $2.5 billion worth of real estate deals in H1 2025, down 8% from $2.7 billion in H1 2024.
Deal Volume: 45 transactions in H1 2025, up from 40 in H1 2024.
Commercial real estate accounted for 62% of ₹6,500 crore in total deal value in Q2 2025.
Blackstone's $378 million acquisition of South City Mall, Kolkata — the quarter's largest private equity transaction
Total Q2 investment stood at ₹6,500 crore, showing a measured slowdown in momentum.
Top contributors included office, warehousing, and retail segments.
Private equity interest remains strong, especially in income-yielding assets.
Investors are focusing on core and core-plus strategies amid market uncertainty.
Q2 Activity: 17 deals worth $1.3 billion, including IPOs and QIPs.
Commercial Real Estate Dominance: Institutional capital continues to flow into commercial platforms.
Capital Market Revival: Return of IPOs, SME REITs, and anticipation of India's largest REIT.
Outlook: Sector poised for a more mature, innovation-led investment cycle in H2 2025.
'The data reflects a sector recalibrating for long-term strength,' said Shabala Shinde, Partner and Real Estate Industry Leader at Grant Thornton Bharat. 'While deal values moderated, institutional capital continues to flow steadily into commercial platforms, reinforcing the asset class' resilience.'
Notably, the revival of IPO and SME REIT activity also signals increasing investor interest in structured real estate products. The anticipation of India's largest-ever REIT listing in the coming months is expected to further cement the capital market's role in funding real estate growth.
In Q2 alone, there were 17 deals worth $1.3 billion, with IPOs and Qualified Institutional Placements (QIPs) returning to the fore. While residential deals declined slightly, commercial real estate saw strong activity across metros—driven by office parks, warehousing hubs, and retail portfolios with long-term lease visibility.
With rising interest from global pension funds, sovereign wealth funds, and domestic institutions, the second half of 2025 is poised for a more mature, innovation-led investment cycle, say experts. The shift indicates a flight to stability amid global volatility, with Grade-A office assets and logistics parks emerging as preferred bets.
In contrast, residential and proptech saw muted action
Residential segment:
Accounted for 23% of total deal volumes in Q2 2025.
Contributed only 10% of the total transaction value, indicating smaller ticket sizes compared to commercial.
Proptech segment:
Made up 15% of total deal volumes.
Represented just 5% of total deal value, reflecting modest deal sizes and lower investor allocation.
Number of M&A transactions: 6 deals
Total deal value: USD 195 million
Annual change: A 45% decline compared to the corresponding quarter last year
This reflects a significant slowdown in M&A activity, highlighting that strategic consolidation in the real estate sector took a backseat in Q2 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
18 hours ago
- Mint
Trump slams the door–Don't give in, chart a new trade path, say experts
New Delhi: India should continue to focus on manufacturing for the world, but with a more diversified 'US-plus" export market, even as President Donald Trump's 25% tariff and an unspecified penalty for trade with Russia have bared vulnerabilities, said experts. 'The latest set of tariff announcements has indeed exposed vulnerabilities in export-dependent growth models, necessitating a strategic recalibration of India's manufacturing framework," said Rishi Shah, partner and economic advisory services leader, Grant Thornton Bharat. 'Our 'Make in India' initiative's emphasis on scaling production capacity remains fundamentally sound, but the current trade environment underscores the need for a more nuanced approach centered on innovation-led industrial development." India must now elevate industrial security to the 'same strategic priority we've accorded food security and energy security over the past decades", said Shah. The US is India's largest export market now, followed by the UAE, the Netherlands and the UK. India has been focusing on boosting manufacturing in export-oriented sectors such as mobile phones, automobiles and components, and pharmaceuticals, especially by offering production incentives. This has been complemented by a calibrated import tariff regime that seeks to gradually increase domestic value addition from mere assembly to more complex operations. Policy makers have also been hoping to reap the benefits from a global supply chain recalibration away from China. Fresh US tariffs, however, renew worries that one of the growth engines, net exports, will continue to face headwinds. The 25% tariff on Indian exports from 1 August would mean India's exports would face a higher barrier in the US market than goods from South Korea (15% tariff rate), the EU (15%) and the UK (10%). 'With trade policies being used as tools of influence by major economies, the goal must be of industrial self-reliance," said Shah of Grant Thornton Bharat. 'This isn't about import substitution, rather about building economic resilience against external shocks and policy volatility." Sachchidanand Shukla, group chief economist at Larsen & Toubro Ltd, described the current trade uncertainty as a short-term issue and said the focus on manufacturing-centred development should stay. 'It is true the world is in a flux currently and there has been a degree of de-globalization playing out in the recent past," he said. 'But India has to pursue negotiations with the US, partner with other like-minded economies and economic blocs and get deeply embedded in the global value chains." India should keep eyes trained on harnessing all global opportunities, whether it is within Asia, which is the fastest growing region, the EU or Latin America, and continue to enter into trade deals, said Shukla. According to Shukla, India's push for scaling up domestic manufacturing capabilities has served well in building self-reliance and it should continue, especially for strategic reasons and also for meeting the demand in a growing economy, which has the potential to double its size in six-seven years. Besides, the global trade pie and the opportunity is very large at over $33 trillion and must be tapped to generate jobs and growth, Shukla added. 'The current uncertainty in trade relations with the US is a short-term bump. What has been announced by the US may not be the final outcome, as we have seen in negotiations with other countries. India's focus on manufacturing should continue, and we must make in India and make for the world," Shukla said. The path forward requires a dual approach, said Shah of Grant Thornton Bharat. That involves maintaining India's trajectory of scaling up manufacturing while pivoting toward innovation, said Shah. 'This means deepening our focus on research and development intensity, technological capabilities and knowledge-based value addition across manufacturing, services and emerging technology sectors," said Shah. 'Priority areas include semiconductor design, biotechnology R&D (research and development), pharmaceutical innovation and precision electronics—domains where our MSME ecosystem can leverage advanced technologies to create globally competitive products."
News18
2 days ago
- News18
Trump's 25% Tariff Shock: IT, Pharma, Steel Among Sectors Likely To Be Hit
Last Updated: Trump's 25% tariff on all Indian imports from August 1 is expected to trigger volatility in key export-driven sectors with significant US exposure With the US administration's surprise decision to impose a 25% tariff on all Indian imports starting August 1, analysts are bracing for targeted volatility across key export-led sectors—particularly those with heavy US exposure. 'Sentimentally, the announcement is viewed as negative," said Narendra Solanki, Head of Fundamental Research at Anand Rathi Shares & Stock Brokers. 'While a short adjustment window may exist, much of the impact appears partly priced in. The exact extent is unclear, making the scenario largely speculative." Key Sectors Under Pressure Automobiles, Electronics, Gems & Jewelry, Processed Foods Krishan Arora, Partner at Grant Thornton Bharat, termed the move a 'defining moment" for Indian exporters and U.S.-India trade. 'The immediate impact could be sharp across autos, electronics, gems and jewelry, and processed foods. Persistent tariffs may dent India's GDP. Export-led MSMEs and manufacturing clusters face notable risks, and even large corporates will need to reassess supply chains and pricing strategies." However, Kunal Shah, Senior Research Analyst at Carnelian Asset Management, offered nuance: not all sectors will suffer equally. 'Some Indian pharma and chemical firms could gain if US buyers pivot from China," he said. Nirav Karkera of Fisdom added, 'IT is already grappling with macro headwinds and a demand slowdown—this news adds to its burden." Top IT firms such as Infosys, HCL Tech, Tech Mahindra, and LTIMindtree—heavily exposed to US retail and manufacturing—may face higher pressure than more diversified players like Coforge, Mphasis, or Persistent Systems. Pharmaceuticals For now, Indian pharma exports are insulated from the tariff shock. 'Pharma formulations and APIs are currently excluded under the April 2025 tariff framework," said Maitri Sheth, Pharma Analyst at Choice Broking. Still, a pending Section 232 investigation into pharma imports creates an overhang. Trump has hinted at future tariffs of up to 200% on generics, unless firms relocate manufacturing to the US within 12–18 months. Analysts believe such extreme duties are unlikely to materialize due to their potential to spike US healthcare costs. India supplies ~45% of US generics and 10–15% of biosimilars. Best-positioned: Cipla and Piramal Pharma (strong US manufacturing presence). Sun Pharma has already indicated it may pass on any new costs to US buyers. Auto Components Indian auto component manufacturers remain vulnerable, despite auto parts being largely exempt under Section 232. 'Export-oriented players like Samvardhana Motherson, Bharat Forge, and Bosch Ltd may feel the heat if demand slows or supply chains are disrupted," said Karkera. Steel & Aluminium These sectors are already under existing U.S. tariffs and are exempt from new duties. But global trade tensions could still influence demand and pricing. 'Steel and aluminium exporters, including Hindalco, Tata Steel, and JSW Steel, may see short-term volatility due to sentiment shifts," said Karkera. Textiles India's textile exports to the U.S. are modest in volume but remain sentiment-sensitive. 'Companies like Welspun India, KPR Mill, and Vardhman Textiles could see temporary selling pressure," Solanki said. Energy & Oil The energy sector is relatively insulated thanks to exemptions for petroleum and electricity-related imports. 'Listed firms like ONGC and Oil India should remain stable," said Solanki. 'But players like Nayara Energy, with more complex global exposure, could face indirect effects." top videos View all Despite the tariff shock, most analysts agree that India's macro fundamentals remain strong.'India has a diversified export base and is less dependent on trade than most peers," said Karkera. 'We're inward-focused, and US trade is a smaller component compared to others in Asia." Shah added, 'Strong liquidity, a rural rebound, and favorable monsoons support the domestic story. Tariff noise aside, the fundamentals are sound." Stay updated with all the latest news on the Stock Market, including market trends, Sensex and Nifty updates, top gainers and losers, and expert analysis. Get real-time insights, financial reports, and investment strategies—only on News18. tags : donald trump view comments Location : New Delhi, India, India First Published: July 31, 2025, 08:32 IST News business » markets Trump's 25% Tariff Shock: IT, Pharma, Steel Among Sectors Likely To Be Hit Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
2 days ago
- Time of India
Pharma exporters expect Trump to act benevolently to them
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Large Indian drug makers, some of which get as much as half their revenue from the US market, may have to work out options to pass on the impact of the tariff that Washington announced Wednesday. However, analysts and industry insiders said the pharma sector may be exempted or the quantum of tariff on it will be Donald Trump said imports from India would face a 25% reciprocal tariff, effective Friday. There will also be an unspecified penalty for continued import of Russian oil, he industry insiders said while the contours of the tariff announcement on India are not yet clear, a 25% tariff is 'steep' for a sector that operates on thin analysts and executives expect Trump to eventually lower the rate to the 10-15% level imposed on some countries in Europe and the UK, they are of the view that companies will be prompted to pass on the dominant share of the cost increase to the customer.'Twenty-five percent is not good for India. However, it looks like a temporary thing and once negotiation happens in bilateral talks between the two countries, it may come down to 10-15%,' said Bino Pathiparampil, head of research at Elara Capital. 'Companies will have to pass on the lion's share to customers.'Vishal Manchanda, pharma analyst at Systematix Group, said the US 'will have to exempt pharma and there will be a likely roll back'.The Indian government said it has 'taken note' of the US announcement and is studying its implications. It also said India and the US have been engaged in negotiations on concluding a fair, balanced and mutually beneficial trade experts said the pharma industry may be spared from or considered separately for the levy as supplies of generic drugs from India are key to keeping healthcare costs affordable in the US. A steep tariff on the sector could lead to drug shortages in certain critical areas such as antibiotics and cancer drugs. Also, it will lead to cost increases that may eventually have to be passed through to the consumer or absorbed by insurance market has been expecting a 10% tariff on pharma imports from India. Even if half of that is passed on to patients or absorbed by insurers, still large Indian pharma companies may face a 3-5% impact on their earnings in fiscal 2027, according to sector analysts and industry Mishra, partner and tax controversy management leader at Grant Thornton Bharat, said the US announcement has not specified any tariff on pharma. 'However, the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet,' Mishra said. 'Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later.'Pharma companies are closely watching the developments around tariffs.A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, chief executive officer Erez Israeli told ET Vohra, managing director and global chief executive at Cipla , told ET last week that he does not see potential tariffs having a 'debilitating effect'. There will be an impact, but it will not derail the business, he had generic drug makers and contract manufacturing organisations such as Dr Reddy's, Zydus Lifesciences Sun Pharma and Cipla, have a big share of their revenue coming from the US is a major supplier of generic medicines to the US market. India exports about $9 billion worth of formulation in value terms to the US, but accounts for 40% of the medicines consumed in that market. In comparison, the European Union has just a single-digit percentage of the market, exporting $140-150 billion of officials are hopeful that Trump will consider a roll back for the pharma sector as it could lead to many negative repercussions for the US.'They may have to roll it back or lower it to 10%,' said a pharma industry executive. 'India and the US have a strong relationship. The US government will perhaps reconsider and work out a balance,' the person said.
